Radioimmunotherapeutic approaches for leukemia: the past, present and future

References

• Caron PC, Dumont L, Scheinberg DA. Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia. Clin Cancer Res 1998; 4: 1421–8
   PubMed Web of Science ®Google Scholar
• Dinndorf PA, Andrews RG, Benjamin D, et al. Expression of normal myeloid-associated antigens by acute leukemia cells. Blood 1986; 67: 1048–53
   PubMed Web of Science ®Google Scholar
• Nakano A, Harada T, Morikawa S, Kato Y. Expression of leukocyte common antigen (CD45) on various human leukemia/lymphoma cell lines. Acta Pathol Jpn 1990; 40: 107–15
   PubMedGoogle Scholar
• Taetle R, Ostergaard H, Smedsrud M, Trowbridge I. Regulation of CD45 expression in human leukemia cells. Leukemia 1991; 5: 309–14
   Google Scholar
• Noworolska A, Harlozinska A, Richter R, Brodzka W. Non-specific cross-reacting antigen (NCA) in individual maturation stages of myelocytic cell series. Br J Cancer 1985; 51: 371–7
   Google Scholar
• Jurcic JG, Caron PC, Nikula TK, et al. Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias. Cancer Res 1995; 55: 5908s–10s
   PubMed Web of Science ®Google Scholar
• Burke JM, Caron PC, Papadopoulos EB, et al. Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias. Bone Marrow Transplant 2003; 32: 549–56
   PubMed Web of Science ®Google Scholar
• Appelbaum F, Matthews D, Eary JF, et al. The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia. Transplantation 1992; 54: 829–33
   PubMed Web of Science ®Google Scholar
• van der Jagt RH, Badger CC, Appelbaum FR, et al. Localization of radiolabeled antimyeloid antibodies in a human acute leukemia xenograft tumor model. Cancer Res 1992; 52: 89–94
   PubMed Web of Science ®Google Scholar
• Matthews DC, Appelbaum FR, Eary JF, et al. Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood 1999; 94: 1237–47
   PubMed Web of Science ®Google Scholar
• Pagel J, Gooley T, Rajendran J, et al. Targeted radiotherapy using 131I-anti-CD45 antibody followed by allogeneic hematopoietic cell transplantation (HCT): the relationships among dosimetry, bone marrow uptake, and relapse. Eur J Nucl Med Mol Imaging 2006; 33: S193
   Google Scholar
• Pagel JM, Appelbaum FR, Eary JF, et al. 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood 2006; 107: 2184–91
   PubMed Web of Science ®Google Scholar
• Blaise D, Maraninchi D, Michallet M, et al. Long-term follow-up of a randomized trial comparing the combination of cyclophosphamide with total body irradiation or busulfan as conditioning regimen for patients receiving HLA-identical marrow grafts for acute myeloblastic leukemia in first complete remission. Blood 2001; 97: 3669–71
   Google Scholar
• Pagel J, Appelbaum F, Sandmaier B , et al 131I-anti-CD45 antibody plus fludarabine, low-dose total body irradiation and peripheral blood stem cell infusion for elderly patients with advanced acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). Blood 2005;106.
   Google Scholar
• Schwartz MA, Lovett DR, Redner A, et al. Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias. J Clin Oncol 1993; 11: 294–303
   PubMed Web of Science ®Google Scholar
• Scheinberg DA, Lovett D, Divgi CR, et al. A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. J Clin Oncol 1991; 9: 478–90
   PubMed Web of Science ®Google Scholar
• Jurcic JG. Antibody therapy of acute myelogenous leukemia. Cancer Biother Radiopharm 2000; 15: 319–26
   PubMed Web of Science ®Google Scholar
• Jurcic J. Potential for myeloablation with yttrium-90-HuM195 (anti-CD33) in myeloid leukemia. J Clin Oncol 2000; 19:8a [Abstract].
   Google Scholar
• Bunjes D, Buchmann I, Duncker C, et al. Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I–II study. Blood 2001; 98: 565–72
   PubMedGoogle Scholar
• Ringhoffer M, Blumstein N, Neumaier B, et al. 188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I–II study. Br J Haematol 2005; 130: 604–13
   PubMed Web of Science ®Google Scholar
• McDevitt MR, Ma D, Lai LT, et al. Tumor therapy with targeted atomic nanogenerators. Science 2001; 294: 1537–40
   PubMed Web of Science ®Google Scholar
• Jurcic JG, Larson SM, Sgouros G, et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood 2002; 100: 1233–9
   PubMed Web of Science ®Google Scholar
• Mulford DA, Scheinberg DA, Jurcic JG. The promise of targeted {alpha}-particle therapy. J Nucl Med 2005; 46(Suppl 1)199S–204S
   PubMedGoogle Scholar
• Waldmann TA, White JD, Carrasquillo JA, et al. Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac. Blood 1995; 86: 4063–75
   PubMed Web of Science ®Google Scholar
• Zhang M, Yao Z, Zhang Z, et al. The anti-CD25 monoclonal antibody 7G7/B6, armed with the {alpha}-emitter 211At, provides effective radioimmunotherapy for a murine model of leukemia. Cancer Res 2006; 66: 8227–32
   Google Scholar
• Zhang M, Yao Z, Patel H, et al. Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1. Proc Natl Acad Sci USA 2007; 104: 8444–8
   PubMed Web of Science ®Google Scholar
• Lin Y, Pagel JM, Axworthy D, et al. A genetically engineered anti-CD45 single-chain antibody–streptavidin fusion protein for pretargeted radioimmunotherapy of hematologic malignancies. Cancer Res 2006; 66: 3884–92
   PubMed Web of Science ®Google Scholar
• Yao Z, Zhang M, Garmestani K, et al. Pretargeted alpha emitting radioimmunotherapy using (213)Bi 1,4,7,10-tetraazacyclododecane-N,N′,N′′,N′′′-tetraacetic acid-biotin. Clin Cancer Res 2004; 10: 3137–46
   Google Scholar
• Zhang M, Zhang Z, Garmestani K, et al. Pretarget radiotherapy with an anti-CD25 antibody–streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts. Proc Natl Acad Sci USA 2003; 100: 1891–5
   PubMed Web of Science ®Google Scholar
• Pagel JM, Hedin N, Drouet L , et al. Conventional and pretargeted radioimmunotherapy using an anti-murine CD45 monoclonal antibody in a syngeneic, disseminated murine leukemia model. Blood 2006; 108.
   Google Scholar
• Buchmann I, Bunjes D, Kotzerke J, et al. Myeloablative radioimmunotherapy with Re-188-anti-CD66 antibody for conditioning of high-risk leukemia patients prior to stem cell transplantation: biodistribution, biokinetics and immediate toxicities. Cancer Biother Radiopharm 2002; 17: 151–63
   Google Scholar
• DeNardo GL, Lamborn KR, Goldstein DS, et al. Increased survival associated with radiolabeled Lym-1 therapy for non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Cancer 1997; 80: 2706–11
   PubMed Web of Science ®Google Scholar
• Friesen C, Glatting G, Koop B, et al. Breaking chemoresistance and radioresistance with [213Bi]anti-CD45 antibodies in leukemia cells. Cancer Res 2007; 67: 1950–8
   PubMed Web of Science ®Google Scholar
• Sandmaier BM, Bethge WA, Wilbur DS, et al. Bismuth 213-labeled anti-CD45 radioimmunoconjugate to condition dogs for nonmyeloablative allogeneic marrow grafts. Blood 2002; 100: 318–26
   PubMed Web of Science ®Google Scholar
• Barbet J, Kraeber-Bodere F, Vuillez JP, et al. Pretargeting with the affinity enhancement system for radioimmunotherapy. Cancer Biother Radiopharm 1999; 14: 153–66
   PubMed Web of Science ®Google Scholar